lunes, 19 de junio de 2017

Neuroblastoma Screening (PDQ®)—Health Professional Version - National Cancer Institute

Neuroblastoma Screening (PDQ®)—Health Professional Version - National Cancer Institute



National Cancer Institute

Neuroblastoma Screening (PDQ®)–Health Professional Version



SECTIONS

Changes to This Summary (06/16/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text about another study of neuroblastoma incidence and mortality which extended follow-up after cessation of the Japanese mass screening program in 2003 beyond that which was reported in previous publications; results of the mass screening program in Japan are consistent with no effect on neuroblastoma mortality and document that the program caused substantial overdiagnosis with no counterbalancing benefit (cited Shinagawa et al. as reference 33).
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
  • Updated: June 16, 2017

No hay comentarios:

Publicar un comentario